In yesterday’s Wall Street session, Royalty Pharma plc (NASDAQ:RPRX) shares traded at $31.95, up 0.03% from the previous session.
RPRX stock price is now 18.21% away from the 50-day moving average and 16.57% away from the 200-day moving average. The market capitalization of the company currently stands at $18.83B.
With the price target maintained at $28, UBS recently Downgraded its rating from Buy to Neutral for Royalty Pharma plc (NASDAQ: RPRX). , while ‘Scotiabank’ rates the stock as ‘Sector Outperform’
A total of 14.12% of the company’s stock is owned by insiders.
During the past 12 months, Royalty Pharma plc has had a low of $24.05 and a high of $32.12. As of last week, the company has a debt-to-equity ratio of 1.11, a current ratio of 1.54, and a quick ratio of 1.54. According to the stock market information, the enterprise value for the company is $24192854016, which is based on a 12.50 price-to-earnings ratio, a 3.47 price-to-earnings-growth ratio, and a beta of 0.50. The fifty day moving average price for RPRX is $26.9072 and a two-hundred day moving average price translates $27.39495 for the stock.
The latest earnings results from Royalty Pharma plc (NASDAQ: RPRX) was released for 2024-09-30. The net profit margin was 50.52% and return on equity was 17.62% for RPRX. The company reported revenue of $564.69 million for the quarter, compared to $536.31 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 5.29 percent. For the current quarter, analysts expect RPRX to generate $743.6M in revenue.
